April 18, 2020 / Ken Alltucker, USA TODAY
When Aimee Blou heard the lupus drug she has relied on for more than a decade promoted as a coronavirus antidote, she visited her pharmacist.
The 40-year-old woman from Stockton, California, was told the decades-old antimalarial drug commonly prescribed for lupus and rheumatoid arthritis was in short supply. She would get only a 30-day refill, not her typical 90-day supply. 
“It’s all backordered,” the pharmacist explained to Blou on March 23. “We are not going to be able to give you these (90-day) refills.”
Hydroxychloroquine, also sold under the brand name Plaquenil, has been touted by President Donald Trump, media personality Mehmet Oz and others as a COVID-19 treatment, though scientific evidence the drug is effective against the virus is lacking.
The renewed interest in chloroquine, an antimalarial drug available since 1944, and the similar drug hydroxychloroquine has made it difficult for pharmacies and hospital chains to manage a limited supplies, leaving patients like Blou fearful the shortage will harm their health.